CL2018000078A1 - Procedimientos y composiciones para el diagnóstico y para el tratamiento de adrenoleucodistrofia. - Google Patents

Procedimientos y composiciones para el diagnóstico y para el tratamiento de adrenoleucodistrofia.

Info

Publication number
CL2018000078A1
CL2018000078A1 CL2018000078A CL2018000078A CL2018000078A1 CL 2018000078 A1 CL2018000078 A1 CL 2018000078A1 CL 2018000078 A CL2018000078 A CL 2018000078A CL 2018000078 A CL2018000078 A CL 2018000078A CL 2018000078 A1 CL2018000078 A1 CL 2018000078A1
Authority
CL
Chile
Prior art keywords
treatment
adrenoleukodystrophy
diagnosis
procedures
compositions
Prior art date
Application number
CL2018000078A
Other languages
English (en)
Inventor
Onofre Aurora Pujol
Otín Manuel Portero
Gras Reinaldo Pamplona
De Munain Arregi Adolfo José López
Font Mariona Jové
Stephane Fourcade
Original Assignee
Administracion General De La Comunidad Autonoma De Euskadi
Univ Lleida
Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell
Fundacio Inst Catalana De Recerca I Estudis Avancats Icrea
Inst De Recerca Biomedica De Lleida Fundacio Dr Pifarre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Administracion General De La Comunidad Autonoma De Euskadi, Univ Lleida, Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell, Fundacio Inst Catalana De Recerca I Estudis Avancats Icrea, Inst De Recerca Biomedica De Lleida Fundacio Dr Pifarre filed Critical Administracion General De La Comunidad Autonoma De Euskadi
Publication of CL2018000078A1 publication Critical patent/CL2018000078A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UN PROCEDIMIENTO DE DIAGNÓSTICO PARA ADRENOLEUCODISTROFIA EN UN SUJETO EN BASE A LA DETERMINACIÓN DE LOS NIVELES DE DIFERENTES MARCADORES. LA INVENCIÓN TAMBIÉN PROPORCIONA UN PROCEDIMIENTO PARA MONITORIZAR LA PROGRESIÓN DE UNA ADRENOLEUCODISTROFIA, UN PROCEDIMIENTO PARA MONITORIZAR EL EFECTO DE UN TRATAMIENTO DE ADRENOLEUCODISTROFIA Y FINGOLIMOD, UN ANÁLOGO, METABOLITO O DERIVADO DEL MISMO, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, PARA SU USO EN EL TRATAMIENTO Y/O PREVENCIÓN DE UNA ADRENOLEUCODISTROFIA.</p>
CL2018000078A 2015-07-14 2018-01-10 Procedimientos y composiciones para el diagnóstico y para el tratamiento de adrenoleucodistrofia. CL2018000078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382366.1A EP3118621A1 (en) 2015-07-14 2015-07-14 Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy

Publications (1)

Publication Number Publication Date
CL2018000078A1 true CL2018000078A1 (es) 2018-07-06

Family

ID=53776537

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000078A CL2018000078A1 (es) 2015-07-14 2018-01-10 Procedimientos y composiciones para el diagnóstico y para el tratamiento de adrenoleucodistrofia.

Country Status (12)

Country Link
US (1) US20190010535A1 (es)
EP (2) EP3118621A1 (es)
JP (1) JP2018529081A (es)
KR (1) KR20180030074A (es)
CN (1) CN107923897A (es)
AU (1) AU2016293068A1 (es)
BR (1) BR112018000749A2 (es)
CA (1) CA2991586A1 (es)
CL (1) CL2018000078A1 (es)
HK (1) HK1253769A1 (es)
MX (1) MX2018000464A (es)
WO (1) WO2017009437A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US20220072309A9 (en) * 2011-05-09 2022-03-10 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
US20200309788A1 (en) * 2017-09-29 2020-10-01 The General Hospital Corporation Methods for identifying and treating adrenomyeloneuropathy (amn)
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR102252167B1 (ko) * 2018-11-22 2021-05-17 연세대학교 산학협력단 X-연관 부신백질이영양증 진단용 바이오마커 조성물
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
FR3132910A1 (fr) * 2022-02-24 2023-08-25 Universite De Bourgogne Methodes pour le pronostic et le suivi des leucodystrophies peroxysomales

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355193A (zh) * 2000-12-01 2002-06-26 复旦大学 一种新的多肽——肾上腺脑白质营养不良相关蛋白10.78和编码这种多肽的多核苷酸
CA2752003A1 (en) 2009-02-24 2010-09-02 Novartis Ag Ceramide-analogous metabolites
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
ES2377381B1 (es) * 2010-05-17 2013-03-14 Fundació Institut De Investigació Biomèdica De Bellvitge (Idibell) Uso de una combinación de n-acetil-cisteína y ácido lipoico para la preparación de un medicamento útil para el tratamiento de una enfermedad con daño axonal y lesiones oxidativas concomitantes.
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
ES2716865T3 (es) * 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2014110154A1 (en) * 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
JP2016519684A (ja) * 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物

Also Published As

Publication number Publication date
AU2016293068A1 (en) 2018-02-01
WO2017009437A1 (en) 2017-01-19
JP2018529081A (ja) 2018-10-04
CA2991586A1 (en) 2017-01-19
US20190010535A1 (en) 2019-01-10
EP3322980A1 (en) 2018-05-23
EP3322980B1 (en) 2020-09-09
KR20180030074A (ko) 2018-03-21
EP3118621A1 (en) 2017-01-18
HK1253769A1 (zh) 2019-07-05
CN107923897A (zh) 2018-04-17
MX2018000464A (es) 2018-09-06
BR112018000749A2 (pt) 2018-09-04

Similar Documents

Publication Publication Date Title
CL2018000078A1 (es) Procedimientos y composiciones para el diagnóstico y para el tratamiento de adrenoleucodistrofia.
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
BR112018072342A2 (pt) métodos e dispositivos para preparação de agentes de contraste de ultrassom
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CL2016002779A1 (es) Composición para el cuidado de la piel
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
WO2016094374A8 (en) Compositions and methods for treatment of friedreich&#39;s ataxia
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2016011746A (es) Casete de fluido con seguro de alineacion que tiene una tolerancia a la inclinacion mejorada, asi como un aparato de tratamiento de la sangre.
CL2019003557A1 (es) Anticuerpos anti-trkb.
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
ITUA20163037A1 (it) Formulazioni per uso nel trattamento o prevenzione di disturbi urologici